Feb 07, 2024
Magda Kordon-Kiszala speaks about the shortcomings of γH2AX at the DDR Inhibitors Summit 2024
The proprietary fluorescence-based platform technology STRIDE™ outperforms non-specific and non-quantifiable, but well-established approaches to DNA damage analysis such as gamma-H2AX assay.
Dec 09, 2024
intoDNA awarded funding through the European Funds for Smart Economy (FENG) under the “Ścieżka SMART” program
Feb 07, 2024
Magda Kordon-Kiszala speaks about the shortcomings of γH2AX at the DDR Inhibitors Summit 2024
Nov 17, 2023
STRIDE validated in human in vivo samples in collaboration with AstraZeneca
Nov 03, 2023
intoDNA exhibits at SITC 2023, the premier cancer immunotherapy conference
Jul 11, 2023
intoDNA to participate in the 2nd Annual Targeted Radiopharmaceuticals Summit US (TRP)
Mar 28, 2023
intoDNA to present and exhibit at the American Association for Cancer Research Annual Meeting 2023
Jul 19, 2022
intoDNA joins the BioInMed initiative gathering key medical biotechnology companies in Poland
Apr 28, 2022
Magda Kordon as an invited speaker at the DNA Repair/Replication Structures & Cancer Conference
Feb 24, 2022
Magda Kordon, CEO attending the 2022 Gordon Research Conference on DNA Damage, Mutation and Cancer
Sep 28, 2021